Comparative efficacy of albendazole and mebendazole against hookworm infection in Laos
| ISRCTN | ISRCTN29126001 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN29126001 |
| Protocol serial number | N/A |
| Sponsor | Swiss National Science Foundation (Switzerland) |
| Funder | Swiss National Science Foundation (Switzerland) |
- Submission date
- 25/04/2008
- Registration date
- 09/10/2008
- Last edited
- 02/05/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Peter Odermatt
Scientific
Scientific
Swiss Tropical Institute
Department of Public Health and Epidemiology
Socinstrasse 57
Basel
4002
Switzerland
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Comparative efficacy of Albendazole and Mebendazole against hookworm infection: Randomised, controlled trial in schoolchildren in Khamkeuth district, Bolikhamxay province, Laos |
| Study acronym | AlMebLaos |
| Study objectives | Albendazole (400 mg single dose) is more effective than mebendazole (500 mg single dose) in clearing hookworm infection. |
| Ethics approval(s) | National Ethics Committee for Health Research, Vientiane, Laos. Date of approval: 01/04/2008 (ref: 170 /NECHR) |
| Health condition(s) or problem(s) studied | Hookworm infection, and other intestinal helminth infections |
| Intervention | Mebendazole (500 mg, single dose, oral) vs albendzole (400 mg, single dose, oral) treatment. |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Albendazole and mebendazole |
| Primary outcome measure(s) |
Hookworm parasite clearance (no hookworm egg in four Kato-Katz slides taken on two stool samples) at 21-23 days after treatment |
| Key secondary outcome measure(s) |
Reduction of intensity of infection (reduction of mean number of hookworm eggs counted on four Kato-Katz slides taken on two different stool samples) at 21-23 days after treatment |
| Completion date | 30/05/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Lower age limit | 6 Years |
| Upper age limit | 16 Years |
| Sex | All |
| Target sample size at registration | 190 |
| Key inclusion criteria | 1. School-child age between 6 and 16 years, both male and female 2. Hookworm infected (at least one of four egg-positive Kato-Katz slide, established on 2 stool samples) |
| Key exclusion criteria | 1. Pregnancy 2. Severe illness 3. Non-consent |
| Date of first enrolment | 28/04/2008 |
| Date of final enrolment | 30/05/2008 |
Locations
Countries of recruitment
- Lao People's Democratic Republic
- Switzerland
Study participating centre
Swiss Tropical Institute
Basel
4002
Switzerland
4002
Switzerland
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/01/2012 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
